期刊
DIABETES CARE
卷 33, 期 7, 页码 1674-1685出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc10-0666
关键词
-
资金
- Amylin Pharmaceuticals, Inc.
- Lilly USA
- Merck Company, Inc.
- Novo Nordisk A/S
- Sanofi-aventis Groupe
- Amylin
- Bayer Diabetes Care
- Eli Lilly
- Mannkind
- Medtronic
- National Institutes of Health (NIH)
- Novo Nordisk
- ResMed
- Life Scan
- American Diabetes Association
Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据